- Home
- CGO vs EQ Comparison
CGO vs EQ Comparison
Compare CGO & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGO | EQ |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.4M | 140.1M |
| IPO Year | 2004 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CGO | EQ |
|---|---|---|
| Price | $13.00 | $1.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 21.6K | ★ 404.3K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 9.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.71 | $0.76 |
| 52 Week High | $14.20 | $3.54 |
Technical Indicators
Market Signals| Indicator | CGO | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 51.30 | 37.91 |
| Support Level | $12.96 | $1.68 |
| Resistance Level | $13.60 | $1.97 |
| Average True Range (ATR) | 0.26 | 0.17 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 59.02 | 10.11 |
Price Performance
Historical ComparisonAbout CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.